Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment

Bacchetti, Tiziana; Campanati, Anna; Ferretti, Gianna; Simonetti, Oriana; Liberati, Giulia; Offidani, Annamaria

doi:10.1111/bjd.12144

Cited by 68 publications

(61 citation statements)

References 39 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It could be underline that a significant weight loss can lead to significant improvements in circulating levels of leptin, and adiponectin with a possible action and inflammatory state [126] . Improvement of insulin resistance and insulin sensitivity and a significant reduction in systemic inflammation could be obtained by the use of TNF-a inhibitors [118][119][120][121][122][123][124] . Thus, given that biological therapies present the potentiality to reduce the TNF-a-related metabolic comorbidities in psoriatic patients, further prospective studies are needed on this issue.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, Puig et al [121] emphasized that Etanercept treatment may provide some potentially favorable modulation of insulin sensitivity, HDL-C, Apo A1 and Apo B:Apo A1 ratio [121] . Finally, an in vitro study focused that the use of Etanercept can lead to a reduction in lipid peroxidation and an improvement in HDL antioxidant and anti-inflammatory properties [122] .…”

Section: The Effect Of Biologic Response Modifiers On Blood Lipidsmentioning

confidence: 99%

See 1 more Smart Citation

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases. Core tip: The review focuses on the multiple physiopathogenetic aspects of the possible link between psoriasis and non-alcoholic fatty liver disease (NAFLD) emphasizing the most recent scientific data. The importance of the multidisciplinary approach to patients affected by psoriasis is underlined and the therapeutic options to treat concomitant psoriasis and NAFLD is discussed evaluating the risk benefit of both biologic and non-biologic therapies.Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 Available from:

show abstract

Section: Resultsmentioning

confidence: 99%

Section: The Effect Of Biologic Response Modifiers On Blood Lipidsmentioning

confidence: 99%

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

show abstract

“…Çünkü metotreksat, dar bant UVB fototerapi, antitümör nekrozis faktör-α PAŞİ skorlarında düzelme, oksidasyon ve lipit peroksidasyon ürünlerinde azalma ile birliktedir (39)(40)(41) . Oksidatif stresin daha yüksek saptandığı uzun hastalık süresi ve PAŞİ skorlarının karşılaştırılması ile bu kısıtlılığı azaltmaya çalıştık.…”

Section: Discussionunclassified

Clinical Value of Antioxidant Enzymes and Oxidative Biomarkers in Psoriasis

Ataş¹,

Hacınecipoğlu²,

Gönül³

et al. 2017

Okmeydani Medical Journal

View full text Add to dashboard Cite

“…odnotowali u pacjentów z łuszczycą po 24 tygodniach leczenia etanerceptem zwiększenie aktywności PON 1 i odwrotną korelację pomiędzy aktywnością enzymu i stężeniem białka C-reaktywnego (ang. C-reactive protein -CRP) [27]. Badacze podkreślili związek paraoksonazy ze stanem zapalnym oraz wpływ etanerceptu na redukcję peroksydacji lipidów.…”

Section: Paraoksonazaunclassified